Replimune Group, Inc. (NASDAQ:REPL) Receives $10.00 Consensus Target Price from Brokerages

Shares of Replimune Group, Inc. (NASDAQ:REPL) have been assigned a consensus recommendation of “Hold” from the ten brokerages that are presently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $10.00.

A number of equities analysts have recently commented on the company. Piper Sandler boosted their price target on Replimune Group from $13.00 to $14.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Replimune Group in a research note on Monday, December 29th. Finally, Wedbush lifted their target price on Replimune Group from $18.00 to $19.00 and gave the company an “outperform” rating in a research report on Wednesday, February 4th.

Replimune Group Stock Performance

Shares of Replimune Group stock opened at $8.41 on Friday. The company has a 50 day moving average of $7.58 and a 200-day moving average of $7.80. The company has a market cap of $694.41 million, a PE ratio of -2.44 and a beta of 0.74. The company has a current ratio of 5.60, a quick ratio of 5.60 and a debt-to-equity ratio of 0.33. Replimune Group has a 1-year low of $2.68 and a 1-year high of $13.24.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.08. As a group, equities research analysts forecast that Replimune Group will post -2.97 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Replimune Group

Institutional investors have recently added to or reduced their stakes in the stock. International Assets Investment Management LLC acquired a new stake in Replimune Group in the fourth quarter valued at approximately $29,000. Russell Investments Group Ltd. increased its holdings in shares of Replimune Group by 3,638.9% during the third quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock worth $33,000 after buying an additional 7,569 shares in the last quarter. CWM LLC lifted its stake in shares of Replimune Group by 248.6% in the 4th quarter. CWM LLC now owns 4,047 shares of the company’s stock valued at $39,000 after acquiring an additional 2,886 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in shares of Replimune Group by 99.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock valued at $58,000 after acquiring an additional 6,873 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Replimune Group during the 2nd quarter valued at $69,000. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.